Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
04:00:00 2026-08-31 pm EDT
|
5-day change | 1st Jan Change | ||
| 33.16 USD | -0.21% |
|
+0.42% | +7.66% |
| Aug. 31 | Nordic stocks in North America: Ericsson fell 1.2% | FW |
| Aug. 31 | Deutsche Bank raises Genmab price target to 2,500 Danish kroner (2,250), reiterates buy | FW |
| Market Cap | 127B 19.69B 16.95B 15.92B 14.53B 27.29B 1,873B 27.49B 189B 73.38B 950B 73.92B 72.31B 3,145B | P/E 2026 * |
26.8x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 146B 22.67B 19.52B 18.33B 16.73B 31.43B 2,157B 31.65B 217B 84.5B 1,094B 85.12B 83.27B 3,622B | EV / Sales 2026 * |
5.04x | EV / Sales 2027 * | 4.08x |
| Free-Float |
95.42% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Genmab A/S
| 1 day | -0.21% | ||
| 1 week | +0.42% | ||
| Current month | +14.86% | ||
| 1 month | +14.86% | ||
| 3 months | +30.29% | ||
| 6 months | +19.88% | ||
| Current year | +7.66% |
| 1 week | 32.54 |  | 34.47 |
| 1 month | 28.09 | | 34.47 |
| Current year | 23.62 | | 35.43 |
| 1 year | 23.62 | | 35.43 |
| 3 years | 17.24 | | 38.8 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | +0.42% | - | - | 19.69B | |
| -1.66% | -4.96% | +49.84% | +88.43% | 68.13B | |
| -2.19% | +1.32% | +44.54% | +88.38% | 63.6B | |
| +2.38% | +2.88% | +38.97% | +13.25% | 25.57B | |
| +2.77% | -1.74% | -16.16% | +456.51% | 26.6B | |
| -0.46% | -9.94% | +0.98% | -15.98% | 25.52B | |
| -9.71% | -0.36% | +245.87% | +377.68% | 18.23B | |
| -1.58% | +0.47% | +29.35% | -19.62% | 19.69B | |
| -1.33% | -6.20% | +0.95% | +541.31% | 15.16B | |
| +0.35% | +0.16% | +46.96% | +144.04% | 13.54B | |
| Average | -1.16% | -2.71% | +49.03% | +186.00% | 30.67B | |
| Weighted average by Cap. | -1.21% | -2.34% | +45.39% | +146.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.97B 4.5B 3.88B 3.64B 3.32B 6.24B 428B 6.29B 43.13B 16.78B 217B 16.9B 16.54B 719B | 33.74B 5.24B 4.51B 4.24B 3.87B 7.27B 499B 7.32B 50.23B 19.54B 253B 19.69B 19.26B 838B |
| Net income | 4.93B 766M 659M 619M 565M 1.06B 72.86B 1.07B 7.34B 2.85B 36.95B 2.88B 2.81B 122B | 7.17B 1.11B 959M 901M 822M 1.54B 106B 1.56B 10.68B 4.15B 53.77B 4.18B 4.09B 178B |
| Net Debt | 19.19B 2.98B 2.57B 2.41B 2.2B 4.14B 284B 4.16B 28.57B 11.12B 144B 11.2B 10.96B 477B | 11.03B 1.71B 1.48B 1.39B 1.26B 2.38B 163B 2.39B 16.41B 6.39B 82.67B 6.43B 6.29B 274B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-31 | $33.16 | -0.21% | 1,733,460 |
| 26-08-28 | $33.23 | -2.55% | 1,518,714 |
| 26-08-27 | $34.10 | +1.04% | 1,866,282 |
| 26-08-26 | $33.75 | -1.78% | 3,086,697 |
| 26-08-25 | $34.36 | +4.06% | 2,027,506 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
